HCV therapy with daclatasvir, PEG-IFN, and RBV after boceprevir-based therapy failure post-liver transplantation in hyper-IgM syndrome

Transplantation. 2014 Apr 27;97(8):e47-8. doi: 10.1097/TP.0000000000000076.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adult
  • Antiviral Agents / administration & dosage
  • Drug Therapy, Combination
  • Hepatitis C, Chronic / complications
  • Hepatitis C, Chronic / drug therapy*
  • Hepatitis C, Chronic / immunology
  • Humans
  • Hyper-IgM Immunodeficiency Syndrome / complications
  • Hyper-IgM Immunodeficiency Syndrome / immunology*
  • Imidazoles / administration & dosage*
  • Immunoglobulin M / immunology
  • Interferon-alpha / administration & dosage*
  • Liver Transplantation*
  • Male
  • Polyethylene Glycols / administration & dosage*
  • Proline / administration & dosage
  • Proline / analogs & derivatives
  • Recombinant Proteins / administration & dosage
  • Ribavirin / administration & dosage*

Substances

  • Antiviral Agents
  • Imidazoles
  • Immunoglobulin M
  • Interferon-alpha
  • Recombinant Proteins
  • Polyethylene Glycols
  • Ribavirin
  • N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide
  • Proline
  • daclatasvir
  • peginterferon alfa-2a